Refining Approaches to Overcome Challenges, Enhance Consistency, and Standardize Scoring and Reporting in HER2-Expressing Solid Tumors

In this program, pathologists and medical oncologists discuss the nuances of HER2 testing across gastrointestinal, lung, and other solid tumors and the impact of testing results on treatment selection via an on-demand webcast, expert commentary, and downloadable slides.

Share

Program Content

Activities

HER2 Testing in GI Cancers
HER2 Testing in Gastrointestinal Cancers
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2025

Expires: March 24, 2026

HER2 Testing in NSCLC
HER2 Alterations and Testing in NSCLC
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2025

Expires: March 24, 2026

HER2 Targeted Therapy
Applying HER2 Testing Results to Treatment Decisions for Patients With Solid Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 25, 2025

Expires: March 24, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Jazz Pharmaceuticals.

AstraZeneca

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals